Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2017 | T-cell therapy: successes and unmet needs

David Maloney • 25 Aug 2017
EHA 2017
Lymphoma

David Maloney, MD, PhD from the Seattle Cancer Care Alliance, Seattle, WA discusses the patients for whom T-cell therapy demonstrates high efficacy. Dr Maloney also describes where the greatest unmet needs lie. This interview was recorded at the 2017 European Hematology Association (EHA) annual congress held in Madrid, Spain.

More from David Maloney

T-cell engagers and CAR T-cells in R/R CLL: clinical data and future directions 12:26
T-cell engagers and CAR T-cells in R/R CLL: clinical data and future directions
Alexey Danilov et al. • 11 Apr 2025
Expanding the CAR platform in NHL
David Maloney et al. • 17 Oct 2023
Highlights from Day 2: addressing challenges in CAR-T therapy for ALL, AML, CLL & more… 14:23
Highlights from Day 2: addressing challenges in CAR-T therapy for ALL, AML, CLL & more…
David Maloney et al. • 30 Apr 2022
Advances in CAR-T therapy for lymphoma 10:21
Advances in CAR-T therapy for lymphoma
Caron Jacobson et al. • 1 May 2022

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals